Last reviewed · How we verify
SKB103 for injection monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SKB103 for injection monotherapy (SKB103 for injection monotherapy) — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SKB103 for injection monotherapy TARGET | SKB103 for injection monotherapy | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SKB103 for injection monotherapy CI watch — RSS
- SKB103 for injection monotherapy CI watch — Atom
- SKB103 for injection monotherapy CI watch — JSON
- SKB103 for injection monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). SKB103 for injection monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/skb103-for-injection-monotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab